10x Genomics (TXG)
(Delayed Data from NSDQ)
$14.86 USD
-0.88 (-5.59%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $14.90 +0.04 (0.27%) 6:42 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for 10x Genomics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 389 | 433 | 588 | 680 | 424 |
Receivables | 115 | 104 | 85 | 51 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 74 | 82 | 60 | 30 | 15 |
Other Current Assets | 19 | 17 | 14 | 13 | 8 |
Total Current Assets | 596 | 635 | 748 | 774 | 481 |
Net Property & Equipment | 280 | 289 | 169 | 73 | 49 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 21 | 27 | 30 | 0 | 0 |
Deposits & Other Assets | 3 | 7 | 11 | 35 | 76 |
Total Assets | 965 | 1,029 | 1,019 | 929 | 606 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 16 | 22 | 17 | 5 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 87 | 92 | 83 | 103 | 37 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 8 | 5 | 4 | 3 |
Total Current Liabilities | 127 | 131 | 110 | 118 | 63 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 9 | 0 | 0 | 0 | 17 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 6 | 14 | 15 | 86 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 224 | 223 | 201 | 190 | 186 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,026 | 1,839 | 1,681 | 1,544 | 682 |
Retained Earnings | -1,284 | -1,029 | -863 | -805 | -262 |
Other Equity | 0 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 741 | 806 | 818 | 739 | 420 |
Total Liabilities & Shareholder's Equity | 965 | 1,029 | 1,019 | 929 | 606 |
Total Common Equity | 741 | 806 | 818 | 739 | 420 |
Shares Outstanding | 119.10 | 115.20 | 112.50 | 108.40 | 96.20 |
Book Value Per Share | 6.22 | 6.99 | 7.27 | 6.82 | 4.37 |
Fiscal Year End for 10x Genomics falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 380 | 372 | 389 | 357 |
Receivables | NA | 91 | 91 | 115 | 104 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 88 | 83 | 74 | 81 |
Other Current Assets | NA | 20 | 21 | 19 | 20 |
Total Current Assets | NA | 579 | 567 | 596 | 562 |
Net Property & Equipment | NA | 263 | 269 | 280 | 285 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 21 | 21 | 21 | 26 |
Deposits & Other Assets | NA | 5 | 3 | 3 | 6 |
Total Assets | NA | 930 | 923 | 965 | 949 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 21 | 20 | 16 | 19 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 63 | 63 | 87 | 65 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 16 | 14 | 13 | 11 |
Total Current Liabilities | NA | 111 | 109 | 127 | 105 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 11 | 10 | 9 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5 | 4 | 10 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 206 | 204 | 224 | 203 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,107 | 2,064 | 2,026 | 1,981 |
Retained Earnings | NA | -1,382 | -1,344 | -1,284 | -1,235 |
Other Equity | NA | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 724 | 719 | 741 | 745 |
Total Liabilities & Shareholder's Equity | NA | 930 | 923 | 965 | 949 |
Total Common Equity | 0 | 724 | 719 | 741 | 745 |
Shares Outstanding | 120.40 | 120.40 | 119.10 | 119.10 | 117.40 |
Book Value Per Share | 0.00 | 6.01 | 6.04 | 6.22 | 6.35 |